Arm 1 Type of group

A Phase III Study to Evaluate Letrozole as Adjuvant Endocrina Therapy for Postmenopausal Women with Receptor (ER and/or PgR) Positive Tumors

A MULTICENTER DOUBLE BLIND, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFECTS OF TWO DIFFERENT DOSIS OF LOSARTAN ON MORBIDITY AND MORTALITY IN PATIENTS WITH SYMPTOMATIC HEART FAILURE INTOLERANT TO ACE INHIBITOR TREATMENT

Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting

ANTIPARASITIC THERAPY FOR NEUROCYSTICERCOSIS: PHASE II / III STUDY ON SAFETY AND EFFECTIVENESS AND COMBINED TREATMENT OF PRAZICUANTEL AND ALBENDAZOLE

A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26-Year-Old Women

An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer. - BEATRICE

A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005

A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ADJUVANT ANTHRACYCLINE/TAXANE BASED CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PATIENTS WITH OPERABLE TRIPLE NEGATIVE BREAST CANCER

A PHASE II, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 400 MG OF RIBOCICLIB IN COMBINATION WITH NON-STEROIDAL AROMATASE INHIBITORS FOR THE TREATMENT OF PRE- AND POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHO RECEIVED NO PRIOR THERAPY FOR ADVANCED DISEASE

HYDROXYCHLOROQUINE TO PREVENT SARS-COV-2 INFECTION

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD˗9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure

COVID-19: A PHASE 2A, PARTIALLY OBSERVER-BLIND, MULTICENTER, CONTROLLED, DOSE-CONFIRMATION CLINICAL TRIAL TO EVALUATE THE SAFETY, REACTOGENICITY AND IMMUNOGENICITY OF THE INVESTIGATIONAL SARS-COV-2 MRNA VACCINE CVNCOV IN ADULTS >60 YEARS OF AGE AND 18 TO 60 YEARS OF AGE

STUDY OF SAFETY, EFFICACY AND TOLERABILITY OF SECUKINUMAB VERSUS PLACEBO, IN COMBINATION WITH SOC THERAPY, IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS

A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE THE EFFICACY OF ADJUVANT DURVALUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN COMPLETELY RESECTED STAGE II-III NSCLC (MERMAID-1)

HERALD

PEMBROLIZUMAB PLUS LENVATINIB PLUS CHEMOTHERAPY FOR THE TREATMENT OF ADVANCED/METASTATIC HER2 NEGATIVE GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA